This study is the first to demonstrate, in both in vitro and in vivo models, that CalebinA effectively suppresses tumor growth and invasion in pancreatic cancer cell lines by inhibiting NF-κB activity and reducing the production of angiogenic factors. Here, NFKB1 is linked to familial pancreatic carcinoma.